

# Mood Disorders

Ilan Kerman, MD, PhD

Department of Psychiatry and Behavioral Medicine

Virginia Tech-Carilion School of Medicine

School of Neuroscience

Virginia Tech

# Disclosures

- No conflicts

# Pre-Post Lecture Exam

In patients with psychiatric illness, what percent of health care service use is for psychiatric treatment?

- a. 20%
- b. 40%
- c. 60%
- d. 80%

# Pre-Post Lecture Exam

What percentage of patients with psychiatric difficulties receive no treatment for their psychiatric condition?

- a. 10%
- b. 25%
- c. 50%
- d. 70%

# Pre-Post Lecture Exam

The most common misdiagnosis of bipolar depression is:

- a) anxiety disorder
- b) substance abuse
- c) borderline personality disorder
- d) unipolar depression
- e) schizophrenia

# Pre-Post Lecture Exam

Treatment of bipolar depression with antidepressants may lead to:

- a) anxiety
- b) greater mood instability
- c) mania induction
- d) psychosis
- e) b and c
- f) all of the above

# Pre-Post Lecture Exam

Which of the following are core symptoms of major depressive disorder?

- a) depressed mood
- b) loss of interest or pleasure
- c) insomnia or hypersomnia
- d) feelings of worthlessness or guilt
- e) suicidal ideation

# Pre-Post Lecture Exam

Which of the following antidepressants is least likely to lead to sexual side effects?

- a) fluoxetine
- b) duloxetine
- c) sertraline
- d) bupropion
- e) venlafaxine



# Prevalence and Burden

# Neuropsychiatric disorders associated with substantial world-wide disability





Figure 1: Contribution by different non-communicable diseases to disability-adjusted life-years worldwide in 2005  
Data adapted from WHO, with permission.<sup>3</sup>

# High proportion of Health Care Costs are used by Complex Patients



--Deloitte & Touche, 2002


# High Utilizers of General Medical Care

- 58% of High Utilizers have panic disorder, generalized anxiety disorder, or depression
- Top 10% Utilizers Account for:
  - 29% of all PC visits
  - 52% of all specialty visits
  - 40% of in-hospital days
  - 26% of all prescriptions

# PSYCHIATRY in PRIMARY CARE

- Less than half of primary care patients with mental illness receive any treatment
- 50-70% MDD is not accurately diagnosed or treated in the primary setting
- Roughly 80% of all antidepressants are prescribed by non-psychiatrists
- More than half of primary care patients on antidepressants do not meet criteria for MDD
- Only 1/3 of internal medicine residents are comfortable treating MDD

# Poor Treatment of Mental Illness



- 33% of those treated receive "minimally adequate care"
- Only 40% of seriously mentally ill are treated

- annually 30.5% of the population (90.3 million Americans) have mental illness
- in 58.6 million, it is *moderate to severe*

# Depressed Patients have Higher Healthcare Utilization


	<u>Depressed</u>	<u>Non-Depressed</u>	<i>p</i>
	(N = 714)	(N = 14,472)	
• Primary Care Visits	5.3	2.9	<.001
• Specialist Referrals	1.1	0.5	<.002
• Tests	10.1	6.6	<.001
• Outpatient Charges	\$1,324	\$701	<.001
• Total Healthcare	\$2,808	\$1,891	<.001
• Length of Stay (over DRG)	14.1 (7)	9.5 (3)	<.002

# Untreated Mental Illness Lowers Productivity

<i>Estimated cost to employers (days lost per year for members with poorly managed depression)</i>	
<i>Absenteeism</i>	<i>3.4 - 7.5 days</i>
<i>Productivity Loss</i>	<i>10.1 - 45 days</i>




# Depression Associated with Decreased Functional Status




Wells et.al., JAMA 262:914-919,1989

# Classification and Diagnosis

# Classification of Mood Disorders



# Mood Disorders: DSM-IV Classification



# DSM-5 Classification

- **Depressive Disorders**

- Major Depressive Disorder
- Disruptive Mood Dysregulation Disorder
- Persistent Depressive Disorder (Dysthymia)
- Premenstrual Dysphoric Disorder
- Substance/Medication-Induced Depressive Disorder
- Depressive Disorder due to Another Medical Condition
- Other Specified Depressive Disorder
- Unspecified Depressive Disorder

# DSM-5 Classification

- **Bipolar Disorders**

- Bipolar I Disorder
- Bipolar II Disorder
- Cyclothymic Disorder
- Substance/Medication-Induced Bipolar and Related Disorder
- Bipolar and Related Disorder due to Another Medical Condition
- Other Specified Bipolar and Related Disorder

# Bipolar Disorders

# Bipolar Disorder Challenges

- Prevalence: 1-4% or higher (narrow vs spectrum)
- Onset in young adulthood (for cases >60 years: medical disorders should be first thought)
- Chronic episodic course
- Morbidity (disability, hospitalization, maladjustment, substance problems, psychiatric disorder, medical problems)
- Mortality (suicide, accidents, and medical co-morbidities)



# Bipolar Disorder Challenges

- Onset to proper diagnosis: 3-10 year lag (35% wait >10 years for correct diagnosis)
- Misdiagnoses: unipolar depression (60%); anxiety disorders (26%); schizophrenia (18%); personality disorder (17%); alcohol/substance abuse (14%).
- Significant co-morbidities (e.g., 60% lifetime prevalence of alcohol and drug use disorders)
- Significant complications: cognitive, personal and occupational functioning

# Epidemiology

- Equal prevalence among men and women.
- Manic episodes – more common in males.
- Depressive episodes -- more common in females.
- Rapid cycling – more common in females.
  - rapid cycling >4 episodes manic in 1 yr
- Age of onset—5 to 50 yrs .
- Marital status -- more common in single/divorced.
- Comorbidity—substance use, panic disorder, OCD

# Clinical Features Predictive of Bipolar.

- Bipolar family history.
- High-density, 3 generation pedigrees.
- Trait mood lability (cyclothymia).
- Hyperthymic temperament.
- Hypomania associated with antidepressants.
- Repeated (at least 3 times) loss of efficacy of antidepressants after initial response.
- Depressive mixed state (with psychomotor excitement, irritable hostility, racing thoughts, and sexual arousal during major depression).

# Course of Bipolar I

- Bipolar I often starts with depression --- 75% in females, 67% in males.
- 10-20%-- only manic episodes.
- Untreated manic episodes lasts about 3 months. Hence should not stop drugs before that time.
- Single manic—90% will have another episode.
- After 5 episodes, inter episode interval stabilizes to 6-9 months.
- 5-15% are rapid cyclers.

# Phases of Bipolar Disorder

- Acute mania
- Bipolar depression
- Maintenance

# Treatment: Challenges of Bipolar Disorder

- Complexity of the clinical presentation (heterogeneous symptom picture, co-morbid psychiatric disorders, and medical disorders)
- Recognition of bipolar depression
- Lack of adherence to treatment & education about the illness
- Necessity of phase relevant treatments & life long strategies.

# Treatment Goals

- Acute mania

Rapid onset of action, relief of symptoms, no depression induction

- Bipolar depression

Relief of symptoms, no mania induction

- Maintenance

Prevention of relapse into depression or mania; reduction of co-morbid anxiety

# Selecting Medication(s)

- Phase specific considerations
- Prior response and tolerability
- Medical and psychiatric co-morbidities
- Side effects
- Drug interactions
- Patient preferences



# Acute Mania: FDA Approved

- 1970        Lithium
- 1973        Chlorpromazine
- 1995        Divalproex
- 2004        Carbamazepine ER
- 2005        Divalproex ER

# FDA Approved Atypical Antipsychotics for Mania

- Olanzapine (Zyprexa) 2000\*
- Risperidone (Risperdal) 2003\*\*
- Aripiprazole (Abilify) 2004\*\*
- Quetiapine (Seroquel) 2004\*\*
- Ziprasidone (Geodon) 2004
- Asenapine (Saphris) 2009

\*Adolescent mania (13-17) 2009/\*\*Pediatric mania (10-17):  
RIS 2007/ARI 2008/QTP 2009

# Acute Mania: First-Line

- Severe
  - lithium or divalproex + antipsychotic
- Less severe
  - lithium or divalproex or antipsychotic or carbamazepine ER

**APA Bipolar Guidelines, Revised 2002**

**APA Bipolar Guidelines Watch 2005**

**CANMAT & ISBN Guidelines 2009**

**Weisler et al, J Clin Psych, 2005**


# Second Generation Antipsychotics in Mania

- All apparently effective
- Generally no worsening of depression (unlike conventional antipsychotics)
- Antidepressant effects (e.g., as seen with quetiapine) & some adjunctive mood stabilization effects
- Less EPS but be wary of metabolic risks, especially weight gain (except possibly for aripiprazole & ziprasidone) and abnormalities in glucose, lipids, or prolactin

See also: Cipriani et al, Lancet 2011; 378: 1306-15


# Aripiprazole in Acute Mania:

## Mean Change From Baseline in YMRS




Mean change in YMRS total scores from baseline to trial end point( 21 days)

# Ziprasidone: Efficacy in Acute Mania



\*p<0.01;

Keck et al., Am J Psychiatry 2003;160:741-748



‡p<0.05;

Potkin et al., J Clin Psychopharmacol 2005;25:301-310

# Antipsychotics

- Caution with over-use and off-label use
  - Should not be first-line for anxiety or insomnia
- Be aware of side effects
  - Extrapyrarnidal symptoms
  - Tardive dyskinesia
  - Weight gain
  - Metabolic syndrome
- Be aware of black-box warning
  - Increased risk of death among patients with dementia with atypical antipsychotics

# ADA/APA Consensus Conference on Antipsychotic Drugs

Drug	Weight Gain	Risk for Diabetes	Worsens Lipid Profile
Clozapine (Clozaril)	+++	++	++
Olanzapine (Zyprexa)	+++	++	++
Risperidone (Risperdal) Paliperidone (Invega)	++	+/-	+/-
Quetiapine (Seroquel)	++	+	+
Aripiprazole (Abilify)	+/-	-	-
Ziprasidone (Geodon)	-	-	-

+ = increase effect; - = no effect



# Acute Bipolar Depression


- Symbyax –olanzapine + fluoxetine
- Lamotrigine
- Lurasidone
- Quetiapine
- Cariprazine?
- Treatment resistant – ECT, TMS?, ketamine?

# Maintenance Treatment


- Lithium
  - Thyroid supplementation is frequently necessary.
  - With lithium, develop hypothyroidism
  - Idiopathic thyroid dysfunction
  - Augmentation with T3 or T4
- Valproic acid, quetiapine, or lamotrigine
  - Lamotrigine (200 mg per day) — slow up titration , due to Stevens Johnson syndrome
- Aripiprazole, olanzapine, or risperidone
- Combination: lithium or valproate + SGA

# Depressive Disorders

# Depression Differential



# Checking For Mania...



# Primary MDD Patient Characteristics

- Age of onset—teens to mid 40s
- Sex—Female 2:Male 1
- Family History—increase in depression
- Treatment Response—50% intent to treat; 70% completer
- Course—intermittent with average duration 6 to 12 months
- Recurrence—50% will have a recurrent episode

# Conditions Associated with Mood Symptoms

- Substance abuse
- Concurrent medications
- General medical disorders
- Other causal non-mood psychiatric disorders
- Grief reactions

# Baseline and Follow-up Depression Symptoms: PHQ-9

**Over the last 2 weeks**, how often have you been bothered by any of the following problems? Read each item carefully, and insert the number of your response.

*(Key: Not at all = 0; Several days = 1; More than half the days = 2; Nearly every day = 3)*

1. Little interest or pleasure in doing things \_\_\_\_
2. Feeling down, depressed, or hopeless \_\_\_\_
3. Trouble falling asleep, staying asleep, or sleeping too much \_\_\_\_
4. Feeling tired or having little energy \_\_\_\_
5. Poor appetite or overeating \_\_\_\_
6. Feeling bad about yourself, feeling that you are a failure, or feeling that you have let yourself or your family down \_\_\_\_
7. Trouble concentrating on things such as reading the newspaper or watching television \_\_\_\_
8. Moving or speaking so slowly that other people could have noticed. Or being so fidgety or restless that you have been moving around a lot more than usual \_\_\_\_
9. Thinking that you would be better off dead or that you want to hurt yourself in some way \_\_\_\_

**Total Score for 1 to 9: \_\_\_\_**

*(Scoring Key: Minimal <5; Mild 5 to 9; Moderate 10 to 14; moderately severe 15 to 19; Severe >19)*

**Impairment:** If you checked off any problem on this questionnaire so far, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?

**Not Difficult at All = 0; Somewhat Difficult = 1; Very Difficult = 2; Extremely Difficult = 3**



# Assessing risk for suicide

- Over 50% of those who kill themselves have seen their primary care doctor within one month of doing so.
- Over 50% of suicides will end up in litigation
- Risk Factors
  - Suicidal or homicidal ideation, intent or plan
  - Access to means of suicide
    - Firearms – ask about access
  - Command hallucinations or other psychosis
  - Anxiety
  - History of previous attempt
  - Family history or recent exposure to suicide
  - Substance abuse

# Acute Treatment of Depression

- Patient education/reassurance
- Response times
  - Psychotherapy: 4-8 weeks
  - Medication: 3-6 weeks
  - ECT: 1-3 weeks
- Light: Seasonal Affective Disorder
- Other: Transcranial Magnetic Stimulation

# Patient Education

- Anxiety and Depression are medical illnesses
- Recovery is the rule
- Treatments are effective
- Aim of treatment is complete symptom remission
- Risk of recurrence is significant
- Seek treatment early if anxiety or depression returns

# Major Depression

- Can last for a year without treatment
- High relapse and recurrence rates, particularly without treatment  
→ shorter well periods, increased frequency and severity of illness
- Most common cause of disability in the world
- Lifetime risk 10-25% females, 5-12% men
- Risk factors: stressors, poor social support, early parental loss, family history, negative cognitive style

# Treatment Options

- Psychotherapy
- Pharmacological treatment
  - SSRIs (sertraline, fluoxetine, citalopram, escitalopram, paroxetine)
  - SNRIs (venlafaxine, duloxetine, desvenlafaxine, levomilnacipran)
  - Tricyclics/Tetracyclic (amitriptyline, nortriptyline)
  - Bupropion, mirtazapine
  - MAOIs (phenelzine, tranylcypromine, EMSAM)
- Hormonal Treatment
  - Perimenopausal women
  - Post-partum depression
- Best Treatment-therapy and meds together

# General Treatment Rules

- Often takes 4-6 weeks for response
- Monitor for response versus remission
- Vegetative symptoms tend to improve first, cognitive symptoms take longer
- SSRIs are the first line of treatment for most patients with MDD
- Address biopsychosocial needs and maintain meds for 6-12 months

# Antidepressants are effective in Primary Care Depression

- Both SSRIs and TCAs are effective in primary care
  - Significant benefit seen over placebo after 4 weeks of tx in 14 RCTs
- More adverse effects with TCAs
  - Drop-out rate 10.2% (vs 5.2% for SSRIs)
- Number needed to treat:
  - SSRIs: 7 to 8
  - TCAs: 6 to 16

# Selective Serotonin Reuptake Inhibitors

- Fluoxetine, Paroxetine, Sertraline, Citalopram, Escitalopram, Fluvoxamine
- Produce response rates close to 70%
- Safer and better tolerated than TCA's
- Given once daily
- Starting and therapeutic doses often similar
- Most common side effects include GI symptoms, HA, insomnia, anxiety, and sexual dysfunction



# Novel or Atypical Antidepressants

- Bupropion (NE and DA reuptake inhibition)
- Trazodone (5-HT<sub>2</sub> receptors and alpha-1 adrenergic receptors)
- Venlafaxine, Duloxetine, Milnacipran, Levomilnacipran (NE and 5-HT reuptake blockers – SNRI's)
- Mirtazapine (presynaptic alpha-2 adrenergic antagonist, and 5-HT<sub>2</sub> and 5-HT<sub>3</sub> receptor antagonist)
- Vilazodone (blocks 5-HT reuptake, agonizes 5-HT<sub>1A</sub> receptors)
- Vortioxetine (blocks 5-HT reuptake, antagonizes 5-HT<sub>3</sub> receptors, agonizes 5-HT<sub>1A</sub> receptors)
- EMSAM – daily patch

# Depression and cardiovascular disease

- Depression is an independent risk factor for development of cardiovascular disease.

(Ford 1998, Pennix 2001, Janszky 2007, Van der Kooy 2007)

- Among patients with established CVD, depression is a predictor of future cardiac events and mortality.

(Carney 1988, Ladwig 1991, Frasure-Smith 1995, Barefoot 1996)

- Issues in treatment of depression in patients with CVD:
  - Safety, tolerability
  - Does treatment impact cardiac events? Mortality?

# RCTs of antidepressants to treat depression in pts with CAD

<b>STUDY</b>	<b>SADHART</b>	<b>MIND-IT</b>	<b>CREATE</b>
<b>Antidepressant</b>	<b>sertraline</b>	<b>mirtazapine</b>	<b>citalopram</b>
<b>Patients</b>	<b>MI, Acute coronary syndrome</b>	<b>&gt; 3 months post-MI</b>	<b>Stable outpatients</b>
<b>Efficacy</b>	<b>Yes</b>	<b>Maybe</b>	<b>Yes (Interpersonal Psychother. - No)</b>
<b>Safe</b>	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>
<b>Prevent adverse cardiac outcomes</b>	<b>Maybe, if depression is adequately treated</b>	<b>Maybe, if depression is adequately treated</b>	<b>unknown</b>

# Side-Effects of Antidepressants

	SEXUAL DYSFUNCTION/DECREASED LIBIDO	WEIGHT GAIN	SEDATION	CARDIAC
SSRIs	+++	+ <sup>a</sup>	+/- <sup>a</sup>	0
Venlafaxine	+++	+/-	+/-	+ (↑ BP)
Mirtazapine	+	+++	++	+/-
Bupropion	0	0	0	+/- (↑ BP)
TCAs	++	++	+++	+++ (ECG, BP)

BP, blood pressure; ECG, electrocardiogram abnormalities; SSRIs, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants.

<sup>a</sup> Paroxetine and fluvoxamine are more likely to cause sedation and weight gain.

# Pre-Post Lecture Exam

In patients with psychiatric illness, what percent of health care service use is for psychiatric treatment?

- a. 20%
- b. 40%
- c. 60%
- d. 80%

# Pre-Post Lecture Exam

What percentage of patients with psychiatric difficulties receive no treatment for their psychiatric condition?

- a. 10%
- b. 25%
- c. 50%
- d. 70%

# Pre-Post Lecture Exam

The most common misdiagnosis of bipolar depression is:

- a) anxiety disorder
- b) substance abuse
- c) borderline personality disorder
- d) unipolar depression
- e) schizophrenia

# Pre-Post Lecture Exam

Treatment of bipolar depression with antidepressants may lead to:

- a) anxiety
- b) greater mood instability
- c) mania induction
- d) psychosis
- e) b and c
- f) all of the above



# Pre-Post Lecture Exam

Which of the following are core symptoms of major depressive disorder?

- a) depressed mood
- b) loss of interest or pleasure
- c) insomnia or hypersomnia
- d) feelings of worthlessness or guilt
- e) suicidal ideation

# Pre-Post Lecture Exam

Which of the following antidepressants is least likely to lead to sexual side effects?

- a) fluoxetine
- b) duloxetine
- c) sertraline
- d) bupropion
- e) venlafaxine

# Acknowledgements

- Sarah M. Clinton, PhD
- James Jefferson, MD
- Anita Kablinger, MD
- Roger G. Kathol, M.D.
- Theo Manschreck MD, MPH
- Robert McCarron, MD
- Champakamala H. Rajanna, MD
- Sarah K. Rivelli, MD